<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02691611</url>
  </required_header>
  <id_info>
    <org_study_id>HS-2939</org_study_id>
    <nct_id>NCT02691611</nct_id>
  </id_info>
  <brief_title>Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency</brief_title>
  <acronym>AATD_Epi</acronym>
  <official_title>Defining Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that environmentally influenced histone modifications regulate
      AM mediated inflammation, contributing to a variable clinical course of AATD, and may also
      influence or be influenced by the activity of AAT augmentation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The variable natural clinical course of alpha-1 anti-trypsin deficiency (AATD) disease and
      strong influence of environmental exposures such as smoking, implicate a major role for
      epigenetic mechanisms in modifying AATD disease penetrance. The goal of this study proposal
      is to investigate epigenetic regulation of alveolar macrophage (AM) inflammation and function
      in AATD PiZZ and PiMZ patients. The investigators proposal focuses on epigenetic histone
      modifications and gene expression specifically in AM.

      AAT augmentation therapy, which alters disease symptoms, may also modulate AM epigenetics. To
      identify epigenetic regulation of AM inflammation in AATD in the context of AAT therapy, the
      investigators will perform and computationally integrate ChIP-seq and RNA-seq data. This will
      help elucidate the immunomodulatory mechanisms regulating AATD and provide an epigenetic map
      for diagnosis and targeted treatment. The investigators will test the efficacy of
      FDA-approved histone modifying drugs, such as SAHA and more specific next-generation histone
      modifiers, such as GSK-J4, to modulate AM AATD-associated activity ex vivo.

      The goal of this study is to enroll up to a total of 13 AATD cases and 6 healthy controls.
      All AATD patients will be asked to give a blood sample and/or undergo a bronchoscopy. AATD
      patients will also be asked to undergo a follow up bronchoscopy and/or blood draw after 6
      months if treatment with alpha-1 antitrypsin augmentation therapy is initiated to study the
      changes in these markers after augmentation therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Epigenetic signature of specific inflammation-associated histone modifications from CD14+ macrophages</measure>
    <time_frame>Change from Baseline histones at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epigenetically regulated genomic profile of AATD in AM</measure>
    <time_frame>Change from Baseline polyA RNA at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic mechanisms to regulate gene expression and cell function</measure>
    <time_frame>Change from Baseline epigenetic modified cells at 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Alpha 1-Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>Alpha-1 Antitrypsin</arm_group_label>
    <description>All AATD patients who will start treatment with alpha-1 antitrypsin augmentation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>Healthy controls with no lung diseases</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        -  AATD from clinic

          -  Healthy controls from community
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        AATD

          -  Age between the ages of 18 and 85

          -  Have a diagnosis of AATD PiZZ or PiMZ established by AAT blood levels and Pi
             genotyping

          -  Are not and have not been on AAT augmentation therapy for the past 6 months

          -  Able to tolerate and willing to undergo study procedures

          -  Provide signed informed consent.

        Exclusion Criteria:

        AATD

          1. History of comorbid condition severe enough to significantly increase risks based on
             investigator discretion

          2. Diagnosis of unstable cardiovascular disease including myocardial infarction in the
             past 6 weeks, uncontrolled congestive heart failure, or uncontrolled arrhythmia

          3. PaO2 on room air at rest &lt;50 mmHg or SaO2 on room air at rest &lt;85%

          4. Post bronchodilator FEV1&lt;30% predicted

          5. Use of anticoagulation (patients on warfarin or clopidogrel will be excluded; patients
             on aspirin alone can be studied even with concurrent use)

          6. Dementia or other cognitive dysfunction which in the opinion of the investigator would
             prevent the participant from consenting to the study or completing study procedures

          7. Active pulmonary infection with tuberculosis

          8. History of pulmonary embolism in the past 2 years

          9. Non-COPD obstructive disease (various bronchiolitides, sarcoid, LAM, histiocytosis X)
             or parenchymal lung disease, pulmonary vascular disease, pleural disease, severe
             kyphoscoliosis, neuromuscular weakness, or other cardiovascular and pulmonary disease,
             that, in the opinion of the investigator, limit the interpretability of the pulmonary
             function measures

         10. Prior significant difficulties with pulmonary function testing

         11. Hypersensitivity to or intolerance of albuterol sulfate or ipratropium bromide or
             propellants or excipients of the inhalers

         12. Hypersensitivity to or intolerance of all drugs required for sedation during conscious
             sedation bronchoscopy.

         13. History of Lung volume reduction surgery, lung resection or bronchoscopic lung volume
             reduction in any form

         14. History of lung or other organ transplant

         15. History of large thoracic metal implants (e.g., AICD and/or pacemaker) that in the
             opinion of the investigator limit the interpretability of CT scans

         16. Currently taking &gt;=10mg a day/20mg every other day of prednisone or equivalent
             systemic corticosteroid

         17. Currently taking any immunosuppressive agent excepting systemic corticosteroids

         18. History of lung cancer or any cancer that spread to multiple locations in the body

         19. Current illicit substance abuse, excluding marijuana

         20. Known HIV/AIDS infection

         21. History of or current exposure to chemotherapy or radiation treatments that, in the
             opinion of the investigator, limits the interpretability of the pulmonary function
             measures.

         22. Has a BMI &gt; 40 kg/m2 at baseline exam

         23. Current or planned pregnancy within the study course.

         24. Currently institutionalized (e.g., prisons, long-term care facilities)

         25. Have a genotype of PiMZ and ever received intravenous or inhaled alpha-1 augmentation
             therapy (Alpha-1 Proteinase Inhibitor, A1PI)

        Conditional Exclusions

          1. Participants who present with an upper respiratory infection or pulmonary
             exacerbation, either solely participant-identified or that has been clinically
             treated, in the last six weeks can be rescreened for the study once the six-week
             window has passed.

          2. Participants who present with current use of acute antibiotics or steroids can be
             rescreened for the study â‰¥30 days after discontinuing acute antibiotics/steroids.

             This does not apply to participants who are on chronic prednisone therapy of &lt;10 mg
             per day or &lt;20 mg every other day.

          3. Participants who present with a myocardial infarction or eye, chest, or abdominal
             surgery within six weeks can be rescreened after the six week window has passed.

             Study coordinators should consult with the site principal investigator prior to
             rescreening these participants.

          4. Female participants who present &lt;3 months after giving birth will be asked to
             reschedule their visit until three months have passed since the birth.

          5. Individuals who are PiZZ receiving alpha-1 augmentation therapy (Alpha-1 Proteinase
             Inhibitor, A1PI) must be off augmentation therapy for &gt;6 months to qualify for
             stratified enrollment in the PiZZ group not receiving augmentation therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian P O'Connor, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nabeel Y Hamzeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Sandhaus, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charlton B Strange, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Briana Barkes, MPH</last_name>
    <phone>303-398-1699</phone>
    <email>barkesb@njhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Briana Barkes, MPH</last_name>
      <phone>303-398-1699</phone>
      <email>barkesb@njhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlton Strange, MD</last_name>
      <email>strangec@musc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009 Jun 25;360(26):2749-57. doi: 10.1056/NEJMcp0900449. Review.</citation>
    <PMID>19553648</PMID>
  </reference>
  <reference>
    <citation>Kim WJ, Wood AM, Barker AF, Brantly ML, Campbell EJ, Eden E, McElvaney G, Rennard SI, Sandhaus RA, Stocks JM, Stoller JK, Strange C, Turino G, Silverman EK, Stockley RA, Demeo DL. Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. Respir Res. 2012 Feb 22;13:16. doi: 10.1186/1465-9921-13-16.</citation>
    <PMID>22356581</PMID>
  </reference>
  <reference>
    <citation>Bouchecareilh M, Hutt DM, Szajner P, Flotte TR, Balch WE. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of Î±1-antitrypsin deficiency. J Biol Chem. 2012 Nov 2;287(45):38265-78. doi: 10.1074/jbc.M112.404707. Epub 2012 Sep 20.</citation>
    <PMID>22995909</PMID>
  </reference>
  <reference>
    <citation>Breton CV, Byun HM, Wenten M, Pan F, Yang A, Gilliland FD. Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. Am J Respir Crit Care Med. 2009 Sep 1;180(5):462-7. doi: 10.1164/rccm.200901-0135OC. Epub 2009 Jun 4.</citation>
    <PMID>19498054</PMID>
  </reference>
  <reference>
    <citation>Sanders YY, Ambalavanan N, Halloran B, Zhang X, Liu H, Crossman DK, Bray M, Zhang K, Thannickal VJ, Hagood JS. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012 Sep 15;186(6):525-35. doi: 10.1164/rccm.201201-0077OC. Epub 2012 Jun 14.</citation>
    <PMID>22700861</PMID>
  </reference>
  <reference>
    <citation>Jeffries MA, Dozmorov M, Tang Y, Merrill JT, Wren JD, Sawalha AH. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics. 2011 May;6(5):593-601. Epub 2011 May 1.</citation>
    <PMID>21436623</PMID>
  </reference>
  <reference>
    <citation>Cortessis VK, Thomas DC, Levine AJ, Breton CV, Mack TM, Siegmund KD, Haile RW, Laird PW. Environmental epigenetics: prospects for studying epigenetic mediation of exposure-response relationships. Hum Genet. 2012 Oct;131(10):1565-89. doi: 10.1007/s00439-012-1189-8. Epub 2012 Jun 28. Review.</citation>
    <PMID>22740325</PMID>
  </reference>
  <reference>
    <citation>Akimova T, Beier UH, Liu Y, Wang L, Hancock WW. Histone/protein deacetylases and T-cell immune responses. Blood. 2012 Mar 15;119(11):2443-51. doi: 10.1182/blood-2011-10-292003. Epub 2012 Jan 12. Review.</citation>
    <PMID>22246031</PMID>
  </reference>
  <reference>
    <citation>Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet. 2007 Apr;8(4):253-62. Review.</citation>
    <PMID>17363974</PMID>
  </reference>
  <reference>
    <citation>Feinberg AP. Epigenetics at the epicenter of modern medicine. JAMA. 2008 Mar 19;299(11):1345-50. doi: 10.1001/jama.299.11.1345.</citation>
    <PMID>18349095</PMID>
  </reference>
  <reference>
    <citation>Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-SuÃ±er D, Cigudosa JC, Urioste M, Benitez J, Boix-Chornet M, Sanchez-Aguilera A, Ling C, Carlsson E, Poulsen P, Vaag A, Stephan Z, Spector TD, Wu YZ, Plass C, Esteller M. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10604-9. Epub 2005 Jul 11.</citation>
    <PMID>16009939</PMID>
  </reference>
  <reference>
    <citation>Miller RL, Ho SM. Environmental epigenetics and asthma: current concepts and call for studies. Am J Respir Crit Care Med. 2008 Mar 15;177(6):567-73. doi: 10.1164/rccm.200710-1511PP. Epub 2008 Jan 10. Review.</citation>
    <PMID>18187692</PMID>
  </reference>
  <reference>
    <citation>Yang IV, Schwartz DA. Epigenetic control of gene expression in the lung. Am J Respir Crit Care Med. 2011 May 15;183(10):1295-301. doi: 10.1164/rccm.201010-1579PP. Review.</citation>
    <PMID>21596832</PMID>
  </reference>
  <reference>
    <citation>Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, Hoch B, Kellner W, Kelly JW, Schmidt A, Thomas PJ, Matsumura Y, Skach WR, Gentzsch M, Riordan JR, Sorscher EJ, Okiyoneda T, Yates JR 3rd, Lukacs GL, Frizzell RA, Manning G, Gottesfeld JM, Balch WE. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol. 2010 Jan;6(1):25-33. doi: 10.1038/nchembio.275. Epub 2009 Dec 6.</citation>
    <PMID>19966789</PMID>
  </reference>
  <reference>
    <citation>Mizuno S, Yasuo M, Bogaard HJ, Kraskauskas D, Natarajan R, Voelkel NF. Inhibition of histone deacetylase causes emphysema. Am J Physiol Lung Cell Mol Physiol. 2011 Mar;300(3):L402-13. doi: 10.1152/ajplung.00207.2010. Epub 2010 Dec 17.</citation>
    <PMID>21224215</PMID>
  </reference>
  <reference>
    <citation>Chen X, Barozzi I, Termanini A, Prosperini E, Recchiuti A, Dalli J, Mietton F, Matteoli G, Hiebert S, Natoli G. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2865-74. doi: 10.1073/pnas.1121131109. Epub 2012 Jul 16.</citation>
    <PMID>22802645</PMID>
  </reference>
  <reference>
    <citation>Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol. 2009;49:243-63. doi: 10.1146/annurev-pharmtox-061008-103102. Review.</citation>
    <PMID>18851683</PMID>
  </reference>
  <reference>
    <citation>Natoli G, Testa G, De Santa F. The future therapeutic potential of histone demethylases: A critical analysis. Curr Opin Drug Discov Devel. 2009 Sep;12(5):607-15. Review.</citation>
    <PMID>19736620</PMID>
  </reference>
  <reference>
    <citation>De Santa F, Narang V, Yap ZH, Tusi BK, Burgold T, Austenaa L, Bucci G, Caganova M, Notarbartolo S, Casola S, Testa G, Sung WK, Wei CL, Natoli G. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 2009 Nov 4;28(21):3341-52. doi: 10.1038/emboj.2009.271. Epub 2009 Sep 24.</citation>
    <PMID>19779457</PMID>
  </reference>
  <reference>
    <citation>De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, Natoli G. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell. 2007 Sep 21;130(6):1083-94. Epub 2007 Sep 6.</citation>
    <PMID>17825402</PMID>
  </reference>
  <reference>
    <citation>Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, Eberhard D, Hutchinson S, Jones E, Katso R, Leveridge M, Mander PK, Mosley J, Ramirez-Molina C, Rowland P, Schofield CJ, Sheppard RJ, Smith JE, Swales C, Tanner R, Thomas P, Tumber A, Drewes G, Oppermann U, Patel DJ, Lee K, Wilson DM. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 2012 Aug 16;488(7411):404-8. doi: 10.1038/nature11262.</citation>
    <PMID>22842901</PMID>
  </reference>
  <reference>
    <citation>Natoli G, Ghisletti S, Barozzi I. The genomic landscapes of inflammation. Genes Dev. 2011 Jan 15;25(2):101-6. doi: 10.1101/gad.2018811. Review.</citation>
    <PMID>21245163</PMID>
  </reference>
  <reference>
    <citation>Bouchecareilh M, Balch WE. Proteostasis, an emerging therapeutic paradigm for managing inflammatory airway stress disease. Curr Mol Med. 2012 Aug;12(7):815-26. Review.</citation>
    <PMID>22697348</PMID>
  </reference>
  <reference>
    <citation>DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax. 2004 Mar;59(3):259-64. Review.</citation>
    <PMID>14985567</PMID>
  </reference>
  <reference>
    <citation>Demeo DL, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard S, Burchard E, Stocks JM, Stoller JK, Strange C, Turino GM, Campbell EJ, Silverman EK. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax. 2007 Sep;62(9):806-13. Epub 2007 Mar 27.</citation>
    <PMID>17389752</PMID>
  </reference>
  <reference>
    <citation>Seersholm N, Kok-Jensen A, Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax. 1994 Jul;49(7):695-8. Erratum in: Thorax 1994 Nov;49(11):1184. Thorax 1998 Jan;53(1):78.</citation>
    <PMID>8066566</PMID>
  </reference>
  <reference>
    <citation>Wolff GL, Kodell RL, Moore SR, Cooney CA. Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice. FASEB J. 1998 Aug;12(11):949-57.</citation>
    <PMID>9707167</PMID>
  </reference>
  <reference>
    <citation>Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, Konietzko N. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997 Oct;10(10):2260-3.</citation>
    <PMID>9387950</PMID>
  </reference>
  <reference>
    <citation>Wencker M, Fuhrmann B, Banik N, Konietzko N; Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 2001 Mar;119(3):737-44.</citation>
    <PMID>11243951</PMID>
  </reference>
  <reference>
    <citation>Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002 Jun 1;165(11):1494-8.</citation>
    <PMID>12045122</PMID>
  </reference>
  <reference>
    <citation>Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, Stockley RA. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009 Jun;33(6):1345-53. doi: 10.1183/09031936.00159408. Epub 2009 Feb 5.</citation>
    <PMID>19196813</PMID>
  </reference>
  <reference>
    <citation>Gottlieb DJ, Luisetti M, Stone PJ, Allegra L, Cantey-Kiser JM, Grassi C, Snider GL. Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group. Am J Respir Crit Care Med. 2000 Dec;162(6):2069-72.</citation>
    <PMID>11112116</PMID>
  </reference>
  <reference>
    <citation>Teckman JH, Jain A. Advances in alpha-1-antitrypsin deficiency liver disease. Curr Gastroenterol Rep. 2014 Jan;16(1):367. doi: 10.1007/s11894-013-0367-8. Review.</citation>
    <PMID>24338605</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>February 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2016</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

